The preliminary schedule and programme of the workshop are listed below. The programme will be updated according to the feedback from the speakers, so please watch this space.




(Status 06-06-2018)




WEDNESDAY 24 October 2018


12.30 – 13.15: Registration and sandwich lunch


13.15 – 13.30: Welcome


13.30 – 16.30: Pathology, epidemiology, and genetic predisposition to testicular germ cell cancer


Daniel Berney (London, UK): What is new in the latest WHO classification of testicular tumours and what else needs to be changed.


Ariana Znaor (Lyon, France): Global patterns and trends in testicular cancer incidence


Jason K. Gurney (Wellington, New Zealand): Unexpected features of the epidemiology of testicular cancer among different populations in New Zealand


Katherine McGlynn (Bethesda, MD, USA): Changing trends in the incidence of testicular cancer: are we close to an explanation of ethnic differences?


Short break


Kate Nathanson (Philadelphia, PA, USA): Novel testicular cancer predisposition loci begin to reveal possible mechanisms.


Maria Santa Rocca (Padua, Italy): Association between copy number variations and risk of testicular cancer.



Coffee/tea break (16.30-17.00)



17.00- 19.00: Developmental pathways implicated in the pathogenesis of germ cell malignancy


Walfred Tang (Cambridge, UK): Epigenetic dysregulation of primordial germ cells and gonocytes as a mechanism of transformation to germ cell neoplasia in situ


Jason Heaney (Houston, TX, USA): Insights into malignant transformation of primordial germ cells from non-primate animal models.


Anne Jørgensen (Copenhagen, DK): The involvement of NODAL/Activin pathway in testicular dysgenesis and dysregulation of pluripotency in human fetal germ cells.


Rod Mitchell (Edinburgh, UK): Deregulation of human testicular development by endocrine disruptors; evidence from experimental studies. Implications for testicular cancer in humans?


TBA Short oral presentation


Welcome reception (19.00-20.30)



THURSDAY 25 October 2018


09.00 – 10.30: Disruption of meiosis in pathogenesis of germ cell cancer


Ramsay J. McFarlane (Bangor, Wales, UK): Meiosis-like functions in oncogenesis


Aspasia Ploubidou (Jena, Germany): Spindle misorientation in the aetiology of germ cell disorders, hypofertility and testicular germ cell cancer.


Anne Goriely (Oxford, UK): Spermatocytic tumours: what can this rare TGCT teach us about the fundamental processes operating in the adult male germline?



Coffee/tea break (10.30-11.00)



11.00-13.00: Novel pathways implicated in the pathogenesis of germ cell cancer


Robert S. Weiss (New York, NY, USA): A mouse model of malignant testicular cancer based on KRAS activation and PTEN inactivation


Joanna Selfe (London, UK): IGF1R signalling in primordial germ cells and testicular cancer.


Trine B. Haugen (Oslo, Norway): SPRY4 and SPRY4-IT1 as possible oncogenes in TGCT


TBA Short oral presentation



13.00-14.45: POSTER SESSION 1 and lunch



14.45-16.15: Epigenetics and genomics of germ cell tumours


Hubert Schorle (Bonn, Germany): The plasticity of germ cell cancer and its dependence on the cellular microenvironment.


Leendert H. Looijenga (Rotterdam, the Netherlands): Clinical relevance of (epi)genetic changes during reprograming of GCNIS/seminoma to nonseminomas.


Saud H. Aldubayan (Boston, MA, USA): Genomic changes during transition from germ cell neoplasia in situ to chemoresistant tumors.



Coffee/tea break (16.15-16.45)



16.45-18.00: Immunological aspects of testicular germ cell tumours


Michal Chovanec (Bratislava, Slovakia): Immune mechanisms and possible immune therapy in testicular germ cell tumours.


Kate Loveland (Clayton, VIC, Australia): Cytokins in testicular germ cell cancer.


TBA: Short oral presentation



Free evening



FRIDAY 26 October 2018


9.00-10.30: Germ cell cancer risk in DSD and paediatric germ cell tumours


Leendert Looijenga (Rotterdam, the Netherlands): Risk of germ cell cancer in androgen insensitivity syndrome.


Ewa Rajpert-De Meyts (Copenhagen, Denmark): Risk of germ cell cancer in sex chromosome aneuploidy.


James Amatruda (Dallas, TX, USA): Genomics of paediatric germ cell tumours.


Lindsay Frazier (Boston, MA, USA): Should there be a different therapeutic approach to paediatric vs. adolescent/young adult germ cell tumor patients?



Coffee break (10.30-11.00)



11.00-13.00: Diagnosis og GCNIS and risk classification of overt tumours


Klaus-Peter Dieckmann (Hamburg, Germany): Detection of GCNIS using specific miRNA profiles


Kristian Almstrup (Copenhagen, DK): Is it possible to detect GCNIS/early tumours in semen samples?


Gedske Daugaard (Copenhagen, DK): Risk factors predicting relapse of stage I testicular cancer undergoing surveillance.


Joerg Beyer (Bern, Switzerland): Risk classification in patients with disseminated disease


TBA: Short oral presentation



13.00-14.30: POSTER SESSION 2 and lunch



14.30-16.00: Management of testicular cancer resistant to treatment


Robert Hamilton (Toronto, Canada): Surgical treatment of disseminated GCTs – what is new and why?


Carsten Bokemeyer (Hamburg, Germany): Clinical features and current treatment of refractory germ cell tumours.


Christoph Oing (Hamburg, Germany): Molecular basis of treatment resistance and potential therapeutic targets.



Coffee break (16.00-16.30)



16.30-18.20: Management of late effects in testicular cancer survivors


Jourik A. Gietema (Groningen, the Netherlands): Genetic susceptibility to late effects of chemotherapy in TGCT survivors.


Mikkel Bandak (Copenhagen, DK): Testicular function in long-term survivors of testicular cancer and the effects of androgen replacement therapy.


Jakob Lauritsen (Copenhagen, DK): Risk of cardio-vascular disease in long-term survivors of testicular cancer.


Michael Kreiberg (Copenhagen, DK): Quality of life in long-term survivors of testicular cancer



Concluding remarks and closure



Conference Dinner (19.30-24.00)